Trial Profile
A 12-month, multicenter, randomized, comparative, open-label study to investigate efficacy and safety of reduced level of TACrolimus with equimolar MyforTIC (Enteric coated Mycophenolate Sodium) or Mycophenolate Mofetil in de novo renal transplant recipients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil; Tacrolimus
- Indications Transplant rejection
- Focus Pharmacodynamics
- Acronyms myTACTIC
- Sponsors Novartis
- 12 Feb 2014 Status changed to active, no longer recruiting according to Clinical Trials Registry - India.
- 27 Mar 2012 New trial record